Pharmaceutical developer Mallinckrodt has become a component of the S&P 500 Index.
Mallinckrodt joined the index after completing its acquisition of Questcor Pharmaceuticals last week. The acquisition increased Mallinckrodt's market capitalization, as well as strengthened its balance sheet, cash generation, and leverage position, according to the firm.
